INDOXACARB First draft prepared

Explanation.................................................................................................. 316 Evaluation for acceptable daily intake......................................................... 316 Biochemical aspects ....................................................................... 316 Absorption, distribution and excretion.................................. 316 Biotransformation ................................................................. 319 Toxicological studies...................................................................... 319 Acute toxicity........................................................................ 319 Oral administration....................................................... 319 Dermal administration.................................................. 319 Exposure by inhalation................................................. 320 Dermal and ocular irritation ......................................... 320 Dermal sensitization ..................................................... 320 Short-term studies of toxicity................................................ 323 Long-term studies of toxicity and carcinogenicity................ 332 Genotoxicity.......................................................................... 334 Reproductive toxicity............................................................ 336 Multigeneration studies ................................................ 336 Developmental toxicity ................................................ 337 Special studies....................................................................... 338 Reversibility of haemolytic and body-weight changes. 338 Distribution of C-DPX-JW062 in rat erythrocytes ... 339 Haemolytic potential of N-hydroxy-4(trifluoromethoxy)aniline (INMT713) in rats, dogs, and humans in vitro ...................................................... 339 Haemolytic potential of IN-MT713 in vitro in erythrocytes from normal and glucose-6-phosphate dehydrogenase-deficient humans ................................. 340 Neurotoxicity................................................................ 341 Studies on the insecticidally-inactive enantiomer ........ 342 Studies on insecticidally-active enantiomer ................. 342 Studies with metabolites............................................... 345 Comments.................................................................................................... 347 Toxicological evaluation ............................................................................. 349 References ................................................................................................... 352